FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4305014614> ?p ?o ?g. }

• W4305014614 endingPage "143" @default.
• W4305014614 startingPage "133" @default.
• W4305014614 abstract "Abstract The multicenter observational BiRD study investigated the real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM) in Belgium. This interim analysis reports results for patients with CLL, with a median follow-up of 34 months. Overall, patients had predominantly relapsed/refractory disease (73%) and were elderly (median age 72 years) with high-risk features such as del17p and/or TP53 mutations (59%). Patients were included either prospectively or retrospectively, and the total patient population effectiveness results were adjusted with left truncation. In the effectiveness population ( N = 221: prospective, n = 71; retrospective, n = 150), the overall response rate was 90.0%. Median progression-free survival was 38.3 months (prospective, not estimable; retrospective, 51.5 months) and median overall survival was not yet estimable in the total, prospective and retrospective groups. Treatment-emergent adverse events (TEAEs) for the prospective and retrospective groups are reported separately. Any-grade TEAEs of interest in the prospective/retrospective groups included infections (67.1%/60.1%), diarrhea (20.5%/10.5%), hypertension (16.4%/9.8%) and atrial fibrillation (12.3%/7.2%). Major bleeding was reported in 5.5%/3.3% of prospective/retrospective patients, with little difference observed between those receiving versus not receiving antithrombotic treatment. Discontinuations due to toxicity were reported in 10.5% of patients. Results from this interim analysis show treatment with ibrutinib to be effective and tolerable, with no new safety signals observed. Future analyses will report on longer-term follow-up." @default.
• W4305014614 created "2022-10-14" @default.
• W4305014614 creator A5008065681 @default.
• W4305014614 creator A5015223856 @default.
• W4305014614 creator A5027657185 @default.
• W4305014614 creator A5043471150 @default.
• W4305014614 creator A5046468777 @default.
• W4305014614 creator A5049436277 @default.
• W4305014614 creator A5051698029 @default.
• W4305014614 creator A5053771868 @default.
• W4305014614 creator A5054416214 @default.
• W4305014614 creator A5055404040 @default.
• W4305014614 creator A5064189547 @default.
• W4305014614 creator A5069303553 @default.
• W4305014614 creator A5077699515 @default.
• W4305014614 creator A5082232325 @default.
• W4305014614 creator A5082890044 @default.
• W4305014614 creator A5087176280 @default.
• W4305014614 date "2022-10-13" @default.
• W4305014614 modified "2023-10-10" @default.
• W4305014614 title "Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study" @default.
• W4305014614 cites W2108206643 @default.
• W4305014614 cites W2142099365 @default.
• W4305014614 cites W2191219754 @default.
• W4305014614 cites W2233614027 @default.
• W4305014614 cites W2337485820 @default.
• W4305014614 cites W2343855217 @default.
• W4305014614 cites W2557801192 @default.
• W4305014614 cites W2787916641 @default.
• W4305014614 cites W2790448887 @default.
• W4305014614 cites W2897636215 @default.
• W4305014614 cites W2902034029 @default.
• W4305014614 cites W2902484351 @default.
• W4305014614 cites W2902706178 @default.
• W4305014614 cites W2949379148 @default.
• W4305014614 cites W2952104924 @default.
• W4305014614 cites W2966190920 @default.
• W4305014614 cites W2973195462 @default.
• W4305014614 cites W2980937306 @default.
• W4305014614 cites W3046303902 @default.
• W4305014614 cites W3095638461 @default.
• W4305014614 cites W3097843108 @default.
• W4305014614 cites W3175584083 @default.
• W4305014614 cites W4212805785 @default.
• W4305014614 doi "https://doi.org/10.1007/s44228-022-00020-8" @default.
• W4305014614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36227519" @default.
• W4305014614 hasPublicationYear "2022" @default.
• W4305014614 type Work @default.
• W4305014614 citedByCount "1" @default.
• W4305014614 countsByYear W43050146142023 @default.
• W4305014614 crossrefType "journal-article" @default.
• W4305014614 hasAuthorship W4305014614A5008065681 @default.
• W4305014614 hasAuthorship W4305014614A5015223856 @default.
• W4305014614 hasAuthorship W4305014614A5027657185 @default.
• W4305014614 hasAuthorship W4305014614A5043471150 @default.
• W4305014614 hasAuthorship W4305014614A5046468777 @default.
• W4305014614 hasAuthorship W4305014614A5049436277 @default.
• W4305014614 hasAuthorship W4305014614A5051698029 @default.
• W4305014614 hasAuthorship W4305014614A5053771868 @default.
• W4305014614 hasAuthorship W4305014614A5054416214 @default.
• W4305014614 hasAuthorship W4305014614A5055404040 @default.
• W4305014614 hasAuthorship W4305014614A5064189547 @default.
• W4305014614 hasAuthorship W4305014614A5069303553 @default.
• W4305014614 hasAuthorship W4305014614A5077699515 @default.
• W4305014614 hasAuthorship W4305014614A5082232325 @default.
• W4305014614 hasAuthorship W4305014614A5082890044 @default.
• W4305014614 hasAuthorship W4305014614A5087176280 @default.
• W4305014614 hasBestOaLocation W43050146141 @default.
• W4305014614 hasConcept C126322002 @default.
• W4305014614 hasConcept C141071460 @default.
• W4305014614 hasConcept C167135981 @default.
• W4305014614 hasConcept C188816634 @default.
• W4305014614 hasConcept C197934379 @default.
• W4305014614 hasConcept C2777938653 @default.
• W4305014614 hasConcept C2778461978 @default.
• W4305014614 hasConcept C2778715236 @default.
• W4305014614 hasConcept C2779878957 @default.
• W4305014614 hasConcept C2908647359 @default.
• W4305014614 hasConcept C71924100 @default.
• W4305014614 hasConcept C99454951 @default.
• W4305014614 hasConceptScore W4305014614C126322002 @default.
• W4305014614 hasConceptScore W4305014614C141071460 @default.
• W4305014614 hasConceptScore W4305014614C167135981 @default.
• W4305014614 hasConceptScore W4305014614C188816634 @default.
• W4305014614 hasConceptScore W4305014614C197934379 @default.
• W4305014614 hasConceptScore W4305014614C2777938653 @default.
• W4305014614 hasConceptScore W4305014614C2778461978 @default.
• W4305014614 hasConceptScore W4305014614C2778715236 @default.
• W4305014614 hasConceptScore W4305014614C2779878957 @default.
• W4305014614 hasConceptScore W4305014614C2908647359 @default.
• W4305014614 hasConceptScore W4305014614C71924100 @default.
• W4305014614 hasConceptScore W4305014614C99454951 @default.
• W4305014614 hasFunder F4320337415 @default.
• W4305014614 hasIssue "4" @default.
• W4305014614 hasLocation W43050146141 @default.
• W4305014614 hasLocation W43050146142 @default.
• W4305014614 hasLocation W43050146143 @default.
• W4305014614 hasLocation W43050146144 @default.

• next